SR1369LRB100 19627 ALS 34900 r

1
SENATE RESOLUTION

 
2    WHEREAS, Eczema is a set of skin conditions that cause red,
3itchy, and inflamed skin, and has profound medical,
4psychosocial, and economic effects on patients, families, and
5their communities; and
 
6    WHEREAS, The prevalence of eczema in the United States is
710.1 percent; and
 
8    WHEREAS, Eczema affects over 31.6 million children and
9adults in the United States alone; and
 
10    WHEREAS, Eczema's medical effects include dry, cracked,
11and scaly skin, incessant itch, chronic pain, and sleep
12deprivation; and
 
13    WHEREAS, 41.5 percent of adult eczema patients report
14having a co-occurring diagnosis of depression and 47.9 percent
15report having a co-occurring diagnosis of asthma; and
 
16    WHEREAS, Adults and children with eczema also frequently
17exhibit comorbidities like asthma, allergic rhinitis, food
18allergies, ADHD, bacterial and viral infections, and
19hypertension; and
 

 

 

SR1369- 2 -LRB100 19627 ALS 34900 r

1    WHEREAS, Eczema's disease burden also includes anxiety,
2stress on social and intimate relationships, increased
3suicidal ideation, delayed developmental achievement, reduced
4self-esteem, restrictions on diet and exercise, extensive
5caregiver burdens, and challenges with medication adherence;
6and
 
7    WHEREAS, Eczema results in missed days of school and work
8for patients and caregivers, disability, and reduced ability
9within a patient's chosen profession, unemployment and
10underemployment, and other opportunity costs; and
 
11    WHEREAS, The direct medical costs of the three most common
12types of eczema exceed $2.17 billion, and the indirect medical
13costs exceed $927 million; and
 
14    WHEREAS, Two-thirds of eczema patients report experiencing
15significant access barriers, including high out-of-pocket
16costs and insurance requirements that delay patients' access to
17medications; and
 
18    WHEREAS, There is no cure for eczema, but emerging
19technologies and medications promise a much brighter future for
20eczema patients; therefore, be it
 
21    RESOLVED, BY THE SENATE OF THE ONE HUNDREDTH GENERAL

 

 

SR1369- 3 -LRB100 19627 ALS 34900 r

1ASSEMBLY OF THE STATE OF ILLINOIS, that the month of October
22018 is designated as Eczema Awareness Month and residents are
3encourage to show support for Eczema Awareness.